Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing
- PMID: 18794552
- DOI: 10.1200/JCO.2007.13.4296
Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing
Abstract
Purpose: Polysomy 17 is frequently found in breast cancer and may complicate the interpretation of HER-2 testing results. We investigated the impact of polysomy 17 on HER-2 testing and studied its clinicopathologic significance in relation to HER2 gene amplification.
Patients and methods: In 226 patients with primary invasive breast carcinoma, HER2 gene and chromosome 17 copy numbers were determined by dual-color fluorescent in situ hybridization (FISH). The interpretation of FISH results was based on either absolute HER2 gene copy number or the ratio HER2/chromosome 17. Results were correlated with HER-2 protein expression on immunohistochemistry (IHC), HER2 mRNA expression by reverse transcriptase polymerase chain reaction (RT-PCR), and with various clinicopathologic parameters.
Results: All cases with an equivocal HER-2 result by FISH, either by absolute HER2 copy number (44 of 226 patients; 19.5%) or by the ratio HER2/chromosome 17 (three of 226 patients; 1.3%), displayed polysomy 17. On its own, polysomy 17 was not associated with HER-2 overexpression on IHC or increased HER2 mRNA levels by RT-PCR. Moreover, and in contrast with HER2 gene amplification, polysomy 17 was not associated with high tumor grade, hormone receptor negativity, or reduced disease-free survival.
Conclusion: Polysomy 17 affects HER-2 testing in breast cancer and is a major cause of equivocal results by FISH. We show that tumors displaying polysomy 17 in the absence of HER2 gene amplification resemble more HER-2-negative than HER-2-positive tumors. These findings highlight the need for clinical trials to investigative whether polysomy 17 tumors benefit from HER-2-targeted therapy.
Comment in
-
Polysomy 17 and HER-2 amplification: true, true, and unrelated.J Clin Oncol. 2008 Oct 20;26(30):4856-8. doi: 10.1200/JCO.2008.17.2684. Epub 2008 Sep 15. J Clin Oncol. 2008. PMID: 18794542 No abstract available.
Similar articles
-
[Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):584-8. Zhonghua Bing Li Xue Za Zhi. 2006. PMID: 17134563 Chinese.
-
Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.J Clin Oncol. 2011 Nov 1;29(31):4168-74. doi: 10.1200/JCO.2011.36.0107. Epub 2011 Sep 26. J Clin Oncol. 2011. PMID: 21947821
-
Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.Hum Pathol. 2011 Oct;42(10):1499-504. doi: 10.1016/j.humpath.2010.04.023. Epub 2011 Jun 14. Hum Pathol. 2011. PMID: 21676436
-
HER2 testing in breast cancer: NCCN Task Force report and recommendations.J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. J Natl Compr Canc Netw. 2006. PMID: 16813731 Review.
-
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Ann Pathol. 2011. PMID: 22172120 Review. French.
Cited by
-
Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches.Cancers (Basel). 2023 Sep 14;15(18):4552. doi: 10.3390/cancers15184552. Cancers (Basel). 2023. PMID: 37760522 Free PMC article. Review.
-
Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study.Cancers (Basel). 2022 Nov 16;14(22):5635. doi: 10.3390/cancers14225635. Cancers (Basel). 2022. PMID: 36428728 Free PMC article.
-
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline.Diagn Pathol. 2022 Jan 7;17(1):5. doi: 10.1186/s13000-021-01187-z. Diagn Pathol. 2022. PMID: 34996485 Free PMC article.
-
Validation of HER2 Status in Whole Genome Sequencing Data of Breast Cancers with the Ploidy-Corrected Copy Number Approach.Mol Diagn Ther. 2022 Jan;26(1):105-116. doi: 10.1007/s40291-021-00571-1. Epub 2021 Dec 21. Mol Diagn Ther. 2022. PMID: 34932189 Free PMC article.
-
Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy.Eur J Breast Health. 2021 Mar 31;17(2):128-136. doi: 10.4274/ejbh.galenos.2021.2021-2-9. eCollection 2021 Apr. Eur J Breast Health. 2021. PMID: 33870112 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous